Sanofi stock leads the CAC 40, sole gainer in a declining market
The pharmaceutical laboratory stands out clearly from a declining Paris market. The stock recovers after a difficult quarter, while remaining far from its levels a year ago.
A 2% gain that contrasts with a falling CAC 40
Sanofi gains 1.97% to €72.41 during the session, making it the strongest performer in the index, while the CAC 40 falls 0.65% and the SBF 120 declines 0.68%. The stock rebounds above its 20-day moving average (€71.76, a 0.91% gap), but remains below its 50-day moving average (€74.39) and below its 200-day moving average (€76.94), or 5.89% below the latter. The rebound comes after a decline of 6.37% over three months and 16.22% over one year, a retreat that had brought the stock to its lowest level since early October 2018.
The RSI at 42.72 remains neutral. The support level at €69.99 and the resistance level at €75.43 define the range within which the stock is trading.
The Frankfurt insulin plant, an industrial project expected to reach full capacity in 2032
On the industrial front, the group has launched its insulin production site in Frankfurt, one of the largest facilities of its kind in Europe, according to the October 19 press release. Production of the active ingredient at full capacity is scheduled for 2032, once all authorizations have been obtained. The project, announced in August 2024, received approval in September 2026 from the European Commission for public support provided by Germany, the Hesse state, and the city of Frankfurt.
In terms of valuation, the stock trades at approximately 8.5 times current fiscal year earnings, according to the consensus of surveyed analysts, with expected earnings per share growth of 5.4% year-over-year. The laboratory also repurchased €1.6 billion of its own shares over twelve months, representing 1.9% of its market capitalization.
